5,214 results match your criteria Bullous Pemphigoid


Bullous pemphigoid and neuropsychiatric medications: An influence of drugs or of underlying conditions?

J Am Acad Dermatol 2019 Apr 17. Epub 2019 Apr 17.

Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel; Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.03.091DOI Listing

REPLY to MS#JAAD-D-19-0054 "Bullous pemphigoid and neuropsychiatric medications: An influence of drugs or of underlying conditions?"

J Am Acad Dermatol 2019 Apr 16. Epub 2019 Apr 16.

PEDEGO Research Unit, University of Oulu; Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.04.025DOI Listing

Proinflammatory Cytokine Gene Polymorphisms in Bullous Pemphigoid.

Front Immunol 2019 29;10:636. Epub 2019 Mar 29.

Skin Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Bullous pemphigoid (BP) is a rare autoimmune skin blistering disease, characterized by the presence of autoantibodies against hemidesmosomal autoantigens. Cytokine expression is altered in BP patients, and several of these differently expressed cytokines, including IL-1α, IL-1β, IL-8, and TNF-α, contribute to disease pathogenesis. Since genetic polymorphisms in the genes of these cytokines might be implicated in susceptibility to BP disease, we aimed at testing this implication in susceptibility to BP in an Iranian cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455081PMC

Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient.

Clin Case Rep 2019 Apr 11;7(4):773-775. Epub 2019 Mar 11.

Department of Dermatology Peter MacCallum Cancer Centre Melbourne Victoria Australia.

Pembrolizumab is an immune checkpoint inhibitor with antitumor activity in other organ malignancies. We present this case -demonstrating multiple inflammatory adverse events associated with Pembrolizumab (in a single patient), in order to increase awareness and facilitate earlier identification of the wide-ranging cutaneous side effects associated with immunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452463PMC

Bullous Pemphigoid with Dipeptidyl Peptidase-4 Inhibitors: Clinical Features and Pathophysiology.

J Diabetes Investig 2019 Apr 15. Epub 2019 Apr 15.

Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine.

Bullous pemphigoid (BP) is a rare autoimmune blistering skin disorder, which involves an immune response directed against hemidesmosomal proteins of basal keratinocytes, BP antigen 180 (BP180) and BP antigen 230 (BP230). It manifests as polymorphic pruritus, blisters, erosions and crusts on the skin. It has been classically known that the development of BP can be induced by certain medications such as diuretics, β-blockers, and antibiotics. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jdi.13060
Publisher Site
http://dx.doi.org/10.1111/jdi.13060DOI Listing
April 2019
1 Read

Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults.

J Am Acad Dermatol 2019 Apr 10. Epub 2019 Apr 10.

Assistance Publique-Hôpitaux de Paris, Département de Dermatologie, Hôpital Saint-Louis, Paris, France; Université Paris-Diderot, Sorbonne Paris Cité, Paris, France. Electronic address:

Background: Paraneoplastic pemphigus (PNP) occurs more often in patients with hematologic malignancies (HMs) than in patients with solid cancer. Lung bronchiolitis obliterans (BO) is a severe complication of PNP.

Objective: To determine the precise clinical and biologic features of HM-associated PNP and identify factors associated with mortality and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.03.043DOI Listing
April 2019
1 Read

A case of atezolizumab-induced photodistributed bullous pemphigoid.

Dermatol Ther 2019 Apr 12:e12924. Epub 2019 Apr 12.

Division of Dermatology, University of California, Los Angeles.

Immunotherapy has revolutionized cancer therapy in recent years but is associated with unique immunologically-mediated adverse effects. Immunotherapy-induced bullous pemphigoid is an uncommon but established reaction that portends significant management implication as in most instances systemic treatment is required. We report a case of immunotherapy-associated bullous pemphigoid in a marked photodistribution, highlighting the diverse clinical presentations of this eruption. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12924DOI Listing

Alogliptin-induced bullous pemphigoid associated with HLA-DQB1*03:01: a case report.

Int J Dermatol 2019 Apr 10. Epub 2019 Apr 10.

Department of Dermatology, Osaka Minato Central Hospital, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14456DOI Listing

A new indirect immunofluorescence BIOCHIP method for the serological diagnosis of bullous pemphigoid: A review of literature.

Australas J Dermatol 2019 Apr 9. Epub 2019 Apr 9.

Department of Dermatology, St George Hospital, Sydney, New South Wales, Australia.

The BIOCHIP (Dermatology Mosaic 7, EUROIMMUN, Lubeck, Germany) is a novel multiplex indirect immunofluorescence technique used in the serological diagnosis of bullous pemphigoid. The BIOCHIP method combines the screening of several autoantibodies and target antigen-specific substrates in a single miniature incubation field to allow for simultaneous processing of the most common autoimmune bullous diseases autoantibodies using a single investigation. This manuscript reviews the literature on the validity of the BIOCHIP in the diagnosis of bullous pemphigoid. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.13034DOI Listing

Successful treatment of one case of pemphigoid gestationis complicating with polycystic ovary syndrome.

Dermatol Ther 2019 Apr 8:e12898. Epub 2019 Apr 8.

Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

Pemphigoid gestationis (PG) is a rare, autoimmune, subepidermal bullous dermatosis associated with pregnancy. It's mainly caused by autoantibodies against hemidesmosomal proteins - bullous pemphigoid 180, and usually presents in the second or third trimester of pregnancy sometimes exacerbates spontaneously after delivery. Here we reported a case of PG with polycystic ovary syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12898DOI Listing
April 2019
3 Reads
1.478 Impact Factor

[Anti-laminin 332 mucous membrane pemphigoid with irreversible ocular and tracheobronchial involvement : Delayed diagnosis of a severe autoimmune bullous disease].

Hautarzt 2019 Apr 8. Epub 2019 Apr 8.

Klinik für Dermatologie, Allergologie und Venerologie, Universität Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland.

A 53-year-old man presented with a 37-year history of erosive and scarring mucosal lesions of several organs. An initial diagnosis of Stevens-Johnson syndrome was maintained for many years. Due to late correct diagnosis of an anti-laminin 332 mucous membrane pemphigoid and the fact that early, targeted, intensified immunosuppressive therapy was not initiated, the disease led to almost complete loss of vision and obstruction of airways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-019-4402-zDOI Listing
April 2019
1 Read

Milia within resolving bullous pemphigoid lesions.

Proc (Bayl Univ Med Cent) 2019 Jan 14;32(1):90-92. Epub 2019 Jan 14.

Texas A&M College of Medicine, College StationTexas.

Bullous pemphigoid (BP) is a blistering dermatosis characterized by an autoimmune response to two hemidesmosomal proteins, BP180 and BP230. We describe a case of an 80-year-old man diagnosed with BP by clinical features, histopathology, and immunosorbent assay who developed milia within resolving BP lesions. Milia formation during recovery is common in cases of mucous membrane pemphigoid and epidermolysis bullosa acquisita but has rarely been reported in cases of BP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08998280.2018.1528962DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442898PMC
January 2019
4 Reads

Localised bullous pemphigoid overlying knee arthroplasty: a diagnostic challenge.

BMJ Case Rep 2019 Apr 5;12(4). Epub 2019 Apr 5.

Department of Surgery, Arrowe Park Hospital, Wirral, UK.

An elderly Caucasian woman developed bullous pemphigoid (BP) overlying the site of total knee arthroplasty for osteoarthritis 2 days after surgery. The clinical findings were consistent with blistering due to soft tissue swelling, bullous impetigo or allergic contact dermatitis. The blistering spread over weeks to months down the ipsilateral leg and then to the other leg and hips. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-227440DOI Listing
April 2019
5 Reads

Phase 2 trial of nivolumab combined with stereotactic body radiotherapy in patients with metastatic or locally advanced inoperable melanoma.

Int J Radiat Oncol Biol Phys 2019 Apr 2. Epub 2019 Apr 2.

Department of Radiation Oncology, Ghent University Hospital, Belgium; Cancer Research Institute Ghent (CRIG), Belgium.

Purpose: Nivolumab improves survival in metastatic melanoma patients. Unfortunately, most patients do not respond to this treatment. Preclinical data indicates that radiotherapy could work synergistically with nivolumab and improve response rates. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016193056
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2019.03.041DOI Listing
April 2019
4 Reads

Association between serum 25-hydroxyvitamin D concentration and severity of first-diagnosed bullous pemphigoid in older adults.

Arch Gerontol Geriatr 2019 Mar 26;83:28-30. Epub 2019 Mar 26.

School of Medicine, Angers, France; Department of Geriatric Medicine, Angers University Hospital, University Memory Clinic of Angers, Research Center on Autonomy and Longevity, UPRES EA 4638, University of Angers, UNAM, Angers, France; Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada. Electronic address:

Background: Higher vitamin D status has been associated with symptom improvement and decreased risk of various autoimmune disorders. Our objective was to determine whether higher serum 25-hydroxyvitamin D (25OHD) concentration correlated with less severe first-diagnosed bullous pemphigoid (BP) in older inpatients.

Methods: This cross-sectional study was performed from November 2012 to February 2014 among 30 consecutive older inpatients (21 women; mean ± SD, 83 ± 7 years; all Caucasian) with a de novo diagnosis of active BP recruited in the Department of Dermatology of Angers University Hospital, France. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01674943193007
Publisher Site
http://dx.doi.org/10.1016/j.archger.2019.03.015DOI Listing
March 2019
3 Reads

Circulating Bullous Pemphigoid Autoantibodies in the Setting of Negative Direct Immunofluorescence Findings for Bullous Pemphigoid: A Single-Center Retrospective Review.

J Am Acad Dermatol 2019 Mar 27. Epub 2019 Mar 27.

Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address:

Background: Bullous pemphigoid (BP) autoantibody levels are generally elevated in patients with BP but can be present nonspecifically in patients without BP.

Objective: To analyze elevated levels of BP180 or BP230 autoantibodies and clinical findings for patients who had negative direct immunofluorescence (DIF) studies.

Methods: We retrospectively reviewed records of patients seen at our institution between January 1, 2005, and December 31, 2015, who had positive BP180 or BP230 autoantibody levels and a negative DIF study (+ ELISA/-DIF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.03.062DOI Listing

Rituximab Therapy in Patients with Bullous Pemphigoid: A Retrospective Study of 20 Patients.

J Am Acad Dermatol 2019 Mar 25. Epub 2019 Mar 25.

Emory University School of Medicine Department of Dermatology, 1525 Clifton Rd, Atlanta GA 30322. Electronic address:

Background: Bullous pemphigoid (BP) is the most common autoimmune blistering disease requiring treatment with immunosuppressive medications, however finding a therapy that has a sustained durable response and an acceptable side effect profile has been challenging.

Objective: Our study aimed to evaluate the clinical outcomes of patients with BP treated with rituximab therapy at a single academic center.

Methods: A retrospective chart review was performed on 20 patients who received at least 1 dose of rituximab therapy, either as initial therapy for severe BP or recalcitrant disease having failed conventional immunotherapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.03.049DOI Listing

Gliptin-Associated Bullous Pemphigoid: A Valuable Model of the Mechanism of Breakdown of Immune Tolerance against BP180.

J Invest Dermatol 2019 Apr;139(4):755-756

Department of Dermatology, PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. Electronic address:

The study by Plaquevent et al. strongly supports the recent discovery that the use of gliptins is a risk factor for bullous pemphigoid (BP). However, regarding the phenotype of gliptin-associated BP and the necessity of gliptin withdrawal, clinical data remain scarce. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2018.11.025DOI Listing

Clinical, pathologic, and immunologic features of pemphigus herpetiformis: a literature review and proposed diagnostic criteria.

Int J Dermatol 2019 Mar 22. Epub 2019 Mar 22.

Department of Dermatology, Mayo Clinic, Jacksonville, FL, USA.

Pemphigus herpetiformis (PH), a rare type of pemphigus, is characterized by immunologic findings consistent with pemphigus but with a unique clinical and pathologic presentation. PH was first described as resembling dermatitis herpetiformis clinically, but because of its variable presentation, it can also resemble linear immunoglobulin A bullous dermatosis and bullous pemphigoid. We reviewed reported cases to analyze the most frequent clinical, pathologic, and immunologic characteristics and to propose corresponding diagnostic criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14395DOI Listing

Bullous pemphigoid: more than one disease?

Authors:
R J Ludwig

J Eur Acad Dermatol Venereol 2019 Mar;33(3):459-460

Lübeck Institute of Experimental Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15445DOI Listing

[Epidermolysis bullosa acquisita].

Hautarzt 2019 Apr;70(4):265-270

Universitäts-Hautklinik Kiel, Klinik für Dermatologie, Venerologie und Allergologie, UKSH Kiel, Kiel, Deutschland.

Epidermolysis bullosa acquisita (EBA) is a rare acquired subepidermal bullous autoimmune dermatosis, associated with autoantibodies against collagen type VII, the most important component of dermal anchoring fibrils. Blister induction occurs after binding of autoantibodies to collagen type VII, leading to complement activation, recruitment of neutrophils and secretion of proteases. Clinically, the disease is mostly characterized by tense blisters on trauma-exposed body areas which heal with scarring (mechanobullous form of EBA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-019-4387-7DOI Listing
April 2019
1 Read

Presence of anti-BP180 and anti-BP230 in the CSF of patients with bullous pemphigoid and neurologic disease: is there any intrathecal synthesis?

Br J Dermatol 2019 Mar 18. Epub 2019 Mar 18.

Hôpital Bichat, Department of dermatology, Paris, France.

The association between bullous pemphigoïd (BP) and several neurologic diseases (ND) - cerebrovascular and neurodegenerative diseases - is well known and documented by several epidemiologic studies while a pathophysiology link is still undetermined. Auto-antibodies (Ab) directed against BP180 are more frequently found in patients with dementia with a titer-severity correlation, independently of any skin disease. We formulated the hypothesis of a primary anti-neuronal auto-immunity in BP, with secondary skin involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17882DOI Listing

Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report.

Ann Biol Clin (Paris) 2019 Apr;77(2):179-183

Service d'hématologie-immunologie-transfusion, Hôpitaux Universitaires Paris Ile-de-France Ouest, CHU Ambroise Paré, Boulogne-Billancourt, France.

Acquired hemophilia A (AHA) is a rare and potentially severe bleeding disorder caused by circulating autoantibodies directed against factor (F) VIII. Apart from idiopathic cases, AHA is associated with autoimmune diseases, cancers, use of medications, pregnancy and the post-partum period. We report the case of a 78-year-old a male patient presenting with symptoms of a hematoma after a fall three days previously. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/abc.2018.1405DOI Listing
April 2019
2 Reads

Demographics and Autoantibody Profiles of Pemphigoid Patients with Underlying Neurologic Diseases.

J Invest Dermatol 2019 Mar 12. Epub 2019 Mar 12.

The University of Iowa, Department of Dermatology, Iowa City, IA, USA; Iowa City VA Medical Center, Iowa City, IA, USA. Electronic address:

Bullous pemphigoid (BP) is an autoantibody-mediated blistering disease that is often associated with neurologic disease. BP antibodies target two epidermal adhesion molecules, known as BP180 and BP230. Homologues to these proteins are found in the brain, and it is hypothesized that neurologic disease leads to the production of autoantibodies that can cross react with their cutaneous forms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2019.01.034DOI Listing
March 2019
1 Read

[Management of bullous pemphigoid].

Authors:
M Göbel R Eming

Hautarzt 2019 Apr;70(4):236-242

Klinik für Dermatologie und Allergologie, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Baldingerstr., 35043, Marburg, Deutschland.

Background: Bullous pemphigoid, the most common autoimmune blistering disease of the skin in adults, is caused by autoantibodies against hemidesmosomal adhesion proteins (BP180/type XVII collagen and BP230), leading into subepidermal blistering. Therefore patients, mostly older than 70 years, show tight bullae and erosions of the skin and rarely at mucous membranes.

Problem: Usually the disease shows a chronically relapsing course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-019-4390-zDOI Listing
April 2019
4 Reads

[Anti-p200 pemphigoid].

Hautarzt 2019 Apr;70(4):271-276

Klinik für Dermatologie, Allergologie und Venerologie, Universität zu Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland.

Anti-p200 pemphigoid is a rare autoimmune blistering disease. It belongs to the group of pemphigoid diseases and was first described in 1996. The diagnostic gold standard is the combination of (1) linear deposits of immunoreactants at the dermal epidermal junction by direct immunofluorescence microscopy of a perilesional skin biopsy, (2) detection of circulating autoantibodies binding to the dermal side (blister floor) of human salt split skin by indirect immunofluorescence microscopy, and reactivity with a 200 kDa protein (p200) in extract of human dermis by immunoblotting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-019-4376-xDOI Listing
April 2019
1 Read

Bullous systemic lupus erythematosus - a case report.

Autops Case Rep 2019 Jan-Mar;9(1):e2018069. Epub 2019 Feb 25.

Universidade de São Paulo, Hospital Universitário, Department of Internal Medcine. São Paulo, SP, Brazil.

Skin involvement in systemic lupus erythematosus (SLE) occurs in more than 75% of patients with this condition. Vesicles and blisters in lupus erythematosus (LE) may be present in SLE secondary to interface vacuolar changes in the epidermis, in discoid LE also secondary to vacuolar epidermal changes, and in bullous LE secondary to antibodies anti-collagen VII deposits with neutrophilic aggregates. In addition, blisters can occur due to the association of SLE with other autoimmune blistering diseases (e. Read More

View Article

Download full-text PDF

Source
http://www.autopsyandcasereports.org/article/doi/10.4322/acr
Publisher Site
http://dx.doi.org/10.4322/acr.2018.069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394362PMC
February 2019
4 Reads

Anti-BP180 Autoantibodies Are Present in Stroke and Recognize Human Cutaneous BP180 and BP180-NC16A.

Front Immunol 2019 26;10:236. Epub 2019 Feb 26.

Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy Medical Science, Beijing, China.

Current evidence has revealed a significant association between bullous pemphigoid (BP) and neurological diseases (ND), including stroke, but the incidence of BP autoantibodies in patients with stroke has not previously been investigated. Our study aimed to assess BP antigen-specific antibodies in stroke patients. One hundred patients with stroke and 100 matched healthy controls were randomly selected for measurement of anti-BP180/BP230 IgG autoantibodies by enzyme-linked immunosorbent assay (ELISA), salt-split indirect immunofluorescence (IIF), and immunoblotting against human cutaneous BP180 and BP180-NC16A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399406PMC
February 2019
2 Reads

Exacerbation of well-controlled bullous pemphigoid by the administration of a dipeptidyl peptidase-4 inhibitor.

Clin Exp Dermatol 2019 Mar 12. Epub 2019 Mar 12.

Department of Dermatology, Osaka City General Hospital, Osaka, Japan.

The incidence of bullous pemphigoid is increasing recently, partly due to the increase of the use of certain culprit drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, psychotropic drugs, and checkpoint-inhibitors. DPP-4 inhibitors, a class of oral hypoglycemics, block the enzyme dipeptidyl peptidase-4, and can be used to treat diabetes mellitus type 2. Association of bullous pemphigoid and mucous membrane pemphigoid with DPP-4 inhibitors in patients with diabetes has been recently demonstrated. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ced.13962
Publisher Site
http://dx.doi.org/10.1111/ced.13962DOI Listing
March 2019
3 Reads

Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.

Acta Derm Venereol 2019 03 8. Epub 2019 Mar 8.

Department of Pathology, MRC Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland.

Dipeptidyl peptidase-4 inhibitors (DPP-4i or gliptins) increase the risk of developing bullous pemphigoid (BP). To clarify, whether gliptin-associated BP has special features, we analyzed the clinical, histopathological and immunological features of 27 BP patients, 10 of which previously used gliptin medication. Compared to those who had not previously received gliptins, subjects who had, showed higher BP180-NC16A ELISA (enzyme-linked immunosorbent assay) values, fewer neurological co-morbidities and shorter time to remission, but differences were not statistically significant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3166DOI Listing

Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid.

Autoimmun Rev 2019 May 4;18(5):526-534. Epub 2019 Mar 4.

Department of Dermatology, University of Illinois at Chicago, USA. Electronic address:

Bullous pemphigoid and pemphigus constitute two major autoimmune blistering diseases (AIBD) with complicated disease pathomechanisms involving a multitude of cytokines and immunological pathways. The purpose of our literature review of the cytokines and chemokines involved in these AIBDs was to allow for a meta-analysis of studies detailing differential cytokine and chemokine changes in these conditions. Elucidation of inflammatory pathways could lead to more targeted therapies, several of which specific monoclonal antibodies already exist and are used safely for other autoimmune diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.009DOI Listing

B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid.

Sci Rep 2019 Mar 5;9(1):3525. Epub 2019 Mar 5.

Normandie University, UNIROUEN, Rouen University Hospital, Department of Dermatology, French reference center for autoimmune bullous diseases, F76000, Rouen, France.

Bullous Pemphigoid is the most common auto-immune bullous skin disease. It is characterized by the production of auto-antibodies directed against 2 proteins of the hemi-desmosome (BP180 and BP230). We assessed the efficacy and mechanisms of action of rituximab, an anti-CD20 monoclonal antibody, in 17 patients with severe and relapsing type of bullous pemphigoid. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-40203-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401188PMC

Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab.

Eur J Dermatol 2019 Mar 2. Epub 2019 Mar 2.

Section of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2019.3499DOI Listing

Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients.

J Am Acad Dermatol 2019 Feb 27. Epub 2019 Feb 27.

Division of Dermatology, University of Kansas Medical Center, Kansas City. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.01.091DOI Listing
February 2019
3 Reads

Bullous pemphigoid and cancer in Taiwan.

Br J Dermatol 2019 Mar;180(3):451-452

Department of Medical Biometrics and Statistics, University of Luebeck, Ratzeburger Allee 160, Bldg. 24, D-23562, Luebeck, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17519DOI Listing

Bullous Pemphigoid IgG Induces Cell Dysfunction and Enhances the Motility of Epidermal Keratinocytes via Rac1/Proteasome Activation.

Front Immunol 2019 12;10:200. Epub 2019 Feb 12.

Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan.

Bullous pemphigoid (BP) is an autoimmune disease characterized by the formation of blisters, in which autoantibodies mainly target type XVII collagen (ColXVII) expressed in basal keratinocytes. BP IgG is known to induce the internalization of ColXVII from the plasma membrane of keratinocytes through macropinocytosis. However, the cellular dynamics following ColXVII internalization have not been completely elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379344PMC
February 2019
4 Reads

Drug Discovery for Pemphigoid Diseases.

Curr Protoc Pharmacol 2019 03 20;84(1):e55. Epub 2019 Feb 20.

Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.

Pemphigoid diseases (PDs) are a group of autoimmune bullous diseases characterized and caused by autoantibodies targeting structural proteins of the skin and mucous membranes. Chronic inflammation, subepidermal blistering, and often scaring are the clinical characteristics of PDs. Itching and, in severe cases, disabilities resulting from scaring (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpph.55DOI Listing

Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know.

Arch Pathol Lab Med 2019 Feb 20. Epub 2019 Feb 20.

From the Department of Dermatology, Saint Louis University, St Louis, Missouri (Dr Abate);the Departments of Dermatology (Dr Battle),and Pathology (Drs Gardner and Shalin),University of Arkansas for Medical Sciences, Little Rock; and the Department of Dermatology, University of Mississippi Medical Center, Jackson (Dr Emerson).

Context.—: Fatal dermatologic diseases and ones with high morbidity can occur in the inpatient setting. In such cases, prompt and accurate assessment of a bedside skin biopsy is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2018-0239-RADOI Listing
February 2019
3 Reads

The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: Case-control study in a specialized Polish center.

Adv Clin Exp Med 2019 Feb 18. Epub 2019 Feb 18.

Department of Dermatology and Immunodermatology, Medical University of Warsaw, Poland.

Background: Bullous pemphigoid (BP) is the most common autoimmune bullous disease associated with higher mortality and coexisting comorbidities. The strongest relationship has been reported with neurological diseases (NDs) but the particular type of ND differed depending on the study. There are some doubts on the prevalence of other comorbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17219/acem/90922DOI Listing
February 2019
1 Read

Bullous Pemphigoid with Atypical Skin Lesions and Acute Interstitial Nephritis: A Case Report and Focused Literature Review.

Am J Case Rep 2019 Feb 18;20:212-218. Epub 2019 Feb 18.

Department of Internal Medicine, Mount Sinai Hospital, Chicago, IL, USA.

BACKGROUND The hallmark of bullous pemphigoid (BP) is widespread tense blisters arising on normal or erythematous skin, often with marked pruritus, the diagnosis of which is confirmed by direct immunofluorescence (DIF). BP is an autoimmune process that can be induced, though rarely, by medications. Drug-induced BP often has atypical clinical presentation, which requires a good understanding of other dermatological conditions with similar presentations, in particular, bullous subtype of erythema multiforme. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.911422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388647PMC
February 2019

Drugs used for neurological and psychiatric conditions increase the risk of bullous pemphigoid: a case-control study.

J Am Acad Dermatol 2019 Feb 13. Epub 2019 Feb 13.

PEDEGO Research Unit, University of Oulu; Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.02.017DOI Listing
February 2019
1 Read

Pharmacological advances in pemphigoid.

Curr Opin Pharmacol 2019 Feb 12;46:34-43. Epub 2019 Feb 12.

Department of Dermatology, Philipps University, Baldingerstr., Marburg, Germany. Electronic address:

Pemphigoid is the most common autoimmune blistering disease. IgG and IgE autoantibodies against the hemidesmosomal antigens Bullous Pemphigoid (BP) 180 and BP230 are of pathogenic relevance, since autoantibody-antigen binding results in complement activation, immune cells infiltration, impaired hemidesmosomal function, and loss of dermal-epidermal adhesion. Systemic steroids and immunosuppressants are frontline therapies in pemphigoid, but result in substantial morbidity and increased mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2018.12.007DOI Listing
February 2019
4 Reads

Biochip detection of BP180 autoantibodies in blister fluid for the serodiagnosis of bullous pemphigoid: A pilot study.

Medicine (Baltimore) 2019 Feb;98(7):e14514

Dermatology Unit, Department of Medicine, University of Padua, Via Vincenzo Gallucci 4, Padua, Italy.

Bullous pemphigoid is an autoimmune subepidermal blistering skin disease immunologically defined by autoantibodies directed against basement membrane zone antigens, the main of which is BP180. Laboratory tests are essential for diagnosis and include direct immunofluorescence and serologic assessments with indirect immunofluorescence and ELISA. Serology may be performed on blister fluid, in alternative to blood serum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014514DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408141PMC
February 2019

Localized vulvar bullous pemphigoid of childhood: A rare cause of persistent vulvar erosions in children.

Pediatr Dermatol 2019 Feb 14. Epub 2019 Feb 14.

Division of Dermatology, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada.

Localized vulvar bullous pemphigoid of childhood is an excessively rare variant of bullous pemphigoid and affects almost exclusively young girls of 7-12 years of age. In contrast to adult-onset bullous pemphigoid, a prompt response to potent topical corticosteroids is observed in the majority of cases, with a favorable prognosis and rare relapses. We report the case of a 7-year-old girl who presented with this condition. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pde.13771
Publisher Site
http://dx.doi.org/10.1111/pde.13771DOI Listing
February 2019
4 Reads

Severe Refractory Paraneoplastic Mucous Membrane Pemphigoid Successfully Treated With Rituximab.

Front Med (Lausanne) 2019 29;6. Epub 2019 Jan 29.

Department of Dermatology, Venerology and Allergology, Charité- Universitätsmedizin Berlin, Berlin, Germany.

Mucous membrane pemphigoid (MMP) is a rare autoimmune bullous disease of the mucous membranes, which can cause irreversible scarring and is discussed to be associated with cancer, if laminin-332-autoantibodies are present. MMP with severe ocular and laryngeal involvement is difficult to treat and can be treatment-refractory to conventional immunosuppressant therapy. A 67-year-old man with a history of prostate cancer presented to our clinic with sore throat, intraoral bullae, odynophagia, dysphonia, exertional dyspnea, and erosions of the glans penis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2019.00008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362419PMC
January 2019
12 Reads

[Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors].

Nihon Ronen Igakkai Zasshi 2019 ;56(1):43-50

Department of Diabetes, Metabolism, and Endocrinology, Tokyo Metropolitan Geriatric Hospital.

Aim: Bullous pemphigoid (BP) is an autoimmune skin disorder characterized by the production of autoantibodies. Several recent reports have described the occurrence of BP in diabetic patients treated with dipeptidyl peptidase-4 (DPP-4) inhibitors. However, the clinical features of BP in diabetic patients, particularly in those treated with DPP-4 inhibitors, have not yet been examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3143/geriatrics.56.43DOI Listing
January 2019
4 Reads

Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.

J Dermatol 2019 Feb 13. Epub 2019 Feb 13.

Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14813DOI Listing
February 2019

Bullous Pemphigoid-like Skin Eruption during Treatment with Rivaroxaban: A Clinical Case Study.

Eur J Case Rep Intern Med 2018 21;5(3):000724. Epub 2018 Mar 21.

Serviço de Anatomia Patológica, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal.

Little has been documented about hypersensitivity reactions caused by treatment with rivaroxaban. This paper reports a bullous pemphigoid-like skin eruption that occurred in a 76-year-old female patient during rivaroxaban treatment. This case highlights the vigilance required by healthcare workers in recognising potential adverse effects of newly marketed drugs and in making medication changes when necessary. Read More

View Article

Download full-text PDF

Source
https://www.ejcrim.com/index.php/EJCRIM/article/view/724
Publisher Site
http://dx.doi.org/10.12890/2018_000724DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346955PMC
March 2018
3 Reads

The Diagnosis and Blistering Mechanisms of Mucous Membrane Pemphigoid.

Front Immunol 2019 24;10:34. Epub 2019 Jan 24.

Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Mucous membrane pemphigoid (MMP) is a mucous membrane-dominated autoimmune subepithelial blistering disease that is caused by autoantibodies against various autoantigens in basement membrane zone (BMZ) proteins, including collagen XVII (COL17). Clinicians face diagnostic problems in detecting circulating antibodies and targeted antigens in MMP. The diagnostic difficulties are mainly attributed to the low titers of MMP autoantibodies in sera and to heterogeneous autoantigens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357922PMC
January 2019